Method and devices for the removal of psoralens from blood products
申请人:——
公开号:US20020115585A1
公开(公告)日:2002-08-22
Method for removing a pathogen-inactivating compound such as psoralen from a biological fluid such as blood or a blood product. One such method involves treating a blood product which contains a nucleic acid-containing pathogen to be inactivated. This method includes adding a pathogen-inactivating compound such as psoralen to the blood product; irradiating the psoralen and the blood product to form a mixture comprising the blood product, free psoralen, and low molecular weight psoralen photoproducts; and contacting the mixture with a hypercrosslinked resin to remove at least substantially all of the free psoralen and the low molecular weight psoralen photoproducts. A hypercrosslinked resin in this method preferably eliminates a wetting step that a number of other types of resins require before being used to adsorb the pathogen inactivating compound.
Method for inactivating pathogens in blood using photoactivation of
申请人:Cerus Corporation
公开号:US05593823A1
公开(公告)日:1997-01-14
Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.
BATCH DEVICES FOR THE REDUCTION OF COMPOUNDS FROM BIOLOGICAL COMPOSITIONS CONTAINING CELLS AND METHODS OF USE
申请人:——
公开号:US20010018179A1
公开(公告)日:2001-08-30
Methods and devices are provided for reducing the concentration of low molecular weight compounds in a biological composition containing cells while substantially maintaining a desired biological activity of the biological composition. The device comprises highly porous adsorbent particles, and the adsorbent particles are immobilized by an inert matrix.
[EN] COMPOUNDS FOR THE PHOTODECONTAMINATION OF PATHOGENS IN BLOOD<br/>[FR] COMPOSES SERVANT A LA PHOTODECONTAMINATION D'AGENTS PATHOGENES DANS LE SANG
申请人:CERUS CORPORATION
公开号:WO1996014739A1
公开(公告)日:1996-05-23
(EN) Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for tranfusion.(FR) Synthèse de composés de psoralène présentant des substitutions au niveau des positions 4, 4', 5', et 8 qui en permettent la fixation améliorée à l'acide nucléique d'agents pathogènes. L'augmentation des niveaux de fixation du psoralène et la réduction de la mutagénicité décrites permettent une inactivation plus sûre, plus efficace et plus fiable des agents pathogènes présents dans les produits sanguins. L'invention porte également sur des méthodes d'inactivation à l'aide desdits nouveaux psoralènes ne compromettant pas la fonction des produits sanguins destinés à la transfusion.
Absorbents and devices for the reduction of small organic compounds from blood products
申请人:Cerus Corporation
公开号:EP1508345A1
公开(公告)日:2005-02-23
The present invention relates to a system for use in treating a blood product containing a pathogen inactivating agent comprising a biocompatible housing and an adsorbent medium having (1) adsorbent resin particles capable of adsorbing the pathogen inactivating agent, and (2) an inert matrix in which the adsorbent resin particles are immobilized; wherein the immobilized adsorbent particles have a diameter from about 100 µm to about 1200 µm when the system is configured as a batch apparatus, and the immobilized adsorbent particles have a diameter from about 1 µm to about 200 µm when the system is configured as a flow-through apparatus; and wherein said blood product substantially maintains a desired biological activity after treatment with said system.